Platinum-Sensitive Lung Small Cell Carcinoma

Platinum-Sensitive Lung Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05353439	Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	active not recruiting	Phase 1	18	National Cancer Institute (NCI)NIH	1	May 13, 2026	clinicaltrials

Data updated 22 days agoSource updated May 13, 2026source: clinicaltrials